



The evaluation of ovarian reserve and menstrual irregularities in female patients treated with systemic isotretinoin

Sistemik izotretinoin ile tedavi edilen kadın hastalarda over rezervinin ve menstrüel düzensizliklerin değerlendirilmesi

● Pelin Kuteyla Can, ● Emek Kocatürk, ● Veli Mihmanlı*, ● Veysel Sucu**,
● Ece Nur Değirmen-tepe, ● Utkan Kızıltaç

Prof. Dr. Cemil Taşcıoğlu City Hospital, Clinic of Dermatology; *Clinic of Obstetrics and Gynecology; **Clinic of Biochemistry, Istanbul, Turkey

Abstract

Background and Design: Isotretinoin is a widely used retinoid for the treatment of many dermatological conditions notably in acne with many known side effects. This study aims to investigate the effects of isotretinoin on anti-Müllerian hormone (AMH), follicle stimulating hormone (FSH) and total antral follicle count (TAFC) as the indicators of ovarian reserve (OR) and also aims to investigate the frequency of menstrual irregularities (MI).

Materials and Methods: Ninety-two reproductive women were included in this prospective controlled study. Study group is consisted of 32 healthy control, 29 low-dose (0.4-0.6 mg/kg/day mean: 0.56±0.06) and 31 high-dose isotretinoin received patients (0.7-1.1 mg/kg/day mean: 0.94±0.11). AMH, FSH and TAFC were evaluated before and at 6th month of treatment in the treatment group, while AMH and FSH levels were evaluated in the control group.

Results: Mean AMH level of treatment group at the 6th month of treatment was significantly lower than the level prior to treatment and that of the control group (p<0.001, p=0.013). Mean FSH level was increased, and TAFC level was decreased compared to pretreatment period (p=0,912, p=0,824). Seventeen patients (28.3%) had MI during treatment.

Conclusion: Although decrease in antral follicle numbers and increase in FSH levels were not significant, significant decreases in AMH levels may indicate the negative effect of isotretinoin on OR.

Keywords: AMH, isotretinoin, menstrual irregularities, ovarian reserve

Öz

Amaç: İzotretinoin, başta akne olmak üzere birçok dermatolojik hastalığın tedavisinde sıkça kullanılan ve birçok yan etkisi bilinen bir retinoiddir. Bu çalışma, aknesi olan kadın hastalarda izotretinoinin over rezervinin (OR) göstergeleri olan anti-Müllerian hormon (AMH), folikül stimüle edici hormon (FSH) ve total antral folikül sayılarına (TAFS) etkisini ve menstrüel düzensizliklerinin (MD) sıklığını araştırmayı amaçlamaktadır.

Gereç ve Yöntem: Prospektif kontrollü olan bu çalışmaya üreme çağındaki 92 kadın dahil edildi. Çalışma, 32 sağlıklı kontrol, 29 düşük doz izotretinoin alan hasta (0,4-0,6 mg/kg/gün doz ortalaması: 0,56±0,06) ve 31 yüksek doz izotretinoin alan hastadan (0,7-1,1 mg/kg/gün doz ortalaması: 0,94±0,11) oluşmaktaydı. Tedavi grubunun serum AMH, FSH ve TAFS değerleri tedavi öncesi ve tedavinin altıncı ayı için, kontrol grubunun ise serum AMH ve FSH seviyeleri değerlendirilmiştir.

Bulgular: Tedavi grubunun tedavinin altıncı ayındaki ortalama serum AMH değerleri tedavi öncesinden ve kontrol grubundan istatistiksel olarak düşük bulunmuştur (p<0,001, p=0,013). Ortalama serum FSH seviyelerinde artış ve TAFS seviyelerinde tedavi öncesine kıyasla düşüş saptanmıştır (p=0,912, p=0,824). On yedi hastada (%28,3) tedavi sırasında MD geliştiği saptandı.

Sonuç: Ortalama total antral folikül sayılarındaki düşüş ve folikül stimüle edici hormon seviyelerindeki artış anlamlı olmasa da, anti-Müllerian hormon seviyelerinde anlamlı düşüşler, izotretinoinin OR üzerine negatif etkisinin bir sonucu olduğunu destekler niteliktedir.

Anahtar Kelimeler: AMH, izotretinoin, menstrüel düzensizlik, over rezervi

Address for Correspondence/Yazışma Adresi: Pelin Kuteyla Can MD, Prof. Dr. Cemil Taşcıoğlu City Hospital, Clinic of Dermatology, İstanbul, Turkey

Phone: +90 535 635 15 38 E-mail: pulkumen@gmail.com **Received/Geliş Tarihi:** 13.09.2019 **Accepted/Kabul Tarihi:** 04.03.2020

ORCID: orcid.org/0000-0002-9124-5817

Introduction

Isotretinoin (13-cis-retinoic acid) is a widely used retinoid for the treatment of many dermatological conditions notably in acne¹. It has been approved by the Food and Drug Administration at 1982 for patients with severe recalcitrant nodulocystic acne and, it is the only molecule that acts on all four steps of the pathogenesis^{2,3}. Isotretinoin is not only beneficial for dermatologic conditions, it is also used for many cancers and lymphomas by promoting differentiation⁴. It is a well-known and widely studied molecule with many side effects including mucocutaneous, rheumatologic, ophthalmic, gastrointestinal, neuromuscular, psychiatric, and laboratory abnormalities^{3,4}. Besides its well-known side effects, there are still unknown side effects and there is a lot of concern about isotretinoin's effect on fertility. There are only few studies available in the literature that investigate isotretinoin's effects on ovarian reserve (OR)⁵⁻¹⁰.

Isotretinoin mainly acts on sebum suppression by sebocyte apoptosis which is induced by isotretinoin-induced expression of tumour necrosis factor-related apoptosis-inducing ligand, insulin-like growth factor binding protein-3 and neutrophil gelatinase-associated lipocalin¹¹. Although apoptosis may participate at the main mechanism of action of the drug, it may also be the explanation for most of the adverse effects of isotretinoin, including impairment of OR.

This study aims to investigate isotretinoin's effects on anti-Mullerian hormone (AMH), follicle stimulating hormone (FSH) and total antral follicle count (T AFC) as the indicators of OR by a different dose manner and also aims to investigate the frequency of menstrual irregularities (MI) in isotretinoin treated female acne patients.

Materials and Methods

Patient selection and data collection

Ninety-two women in reproductive-age (15-34 years) were included in this prospective controlled parallel group study. This study was performed between September 2014 and October 2015. Study group consisted of 32 healthy controls, 29 acne patients under low-dose isotretinoin (0.4-0.6 mg/kg/day mean: 0.56±0.06) and 31 acne patients under high-dose isotretinoin (0.7-1.1 mg/kg/day mean: 0.94±0.106). Patients with MI, polycystic ovary syndrome (PCOS), or any ovarian pathology (endometriosis or ovarian surgery), who had hormonal therapy, systemic chemotherapy (CT), immunosuppressants, antidepressants, steroids, mood stabilizers, alcohol, or retinoid treatment, patients with hormonal dysregulation and patients on pregnancy or lactation were excluded from the study.

This study was approved by İstanbul Okmeydanı Training and Research Hospital Institutional Review Board and was conducted according to the Declaration of Helsinki (approval number: 135, date: 05.11.2013). Written informed consent was obtained from all participating patients.

Treatment design, evaluation of serum anti-Mullerian hormone, follicle stimulating hormone level, total antral follicle count and menstrual irregularities

Treatment group was divided as patients under low-dose isotretinoin (n=29, 0.4-0.6 mg/kg/day mean: 0.56±0.06) and patients under high-dose isotretinoin (n=31, 0.7-1.1 mg/kg/day mean: 0.94±0.106). The patients were monitored monthly during isotretinoin treatment and

all patients received oral isotretinoin for 6 months for acne. Treatment group's AMH, FSH and T AFC were evaluated before the treatment and at the 6th month of treatment, while control group's AMH and FSH levels were evaluated once. Patients were also questioned if they had any MI before and during treatment.

Venous blood samples (10 mL) of the patients and the controls were obtained on days 2-5 of the menstrual cycle and samples were centrifuged for 15 min at 4,000 rpm and then stored at -80 °C. Serum AMH levels were analysed with enzyme-linked immunosorbent assay kit (Beckman Coulter, AMH Gen II ELISA A79765), serum FSH levels were analysed with automated electrochemiluminescence system [ROCHE Cobas 8000 (Germany) Elecsys]. All patients were evaluated with suprapubic pelvic ultrasonography (Xario, Toshiba Medical Systems, Japan, 3,5 to 5 mHz, convex probe) on the day 2-5th of the menstruation to count the T AFC by a gynecologist who was blinded to all participants. T AFC was calculated by the sum of the number of antral follicles measuring 2-10 mm in diameter of the each ovaries.

Normal menstrual cycle was defined as cycle intervals of 21-35 days and duration of bleeding of 4-7 days. Increased interval (delay) was termed if the menstrual cycle ran longer than 35 days, and decreased interval was termed if it ran less than 21 days. Abnormally low bleeding, less than 30 mL per menstrual cycle was termed as hypomenorrhea, excessive bleeding, over 90 mL, in a cycle of normal duration was termed as hypermenorrhea.

Statistical Analysis

Statistical analyses were performed using the SPSS software version 22.0. All numerical variables were reported as the mean ± standard deviation, median, frequency and percentages. The levels of significance values for differences in the mean AMH, FSH, T AFC following treatment approach were calculated Wilcoxon signed rank test. Mann-Whitney U test was used to assess the differences in mean age, body mass index (BMI), AMH, FSH levels between the control and the treatment groups and it was also used to compare the differences in mean changes of the AMH, FSH levels and T AFC between the low and the high-dose groups and patients with MI and without MI. All analyses were performed by using non-parametric methods. Statistical significance was achieved at p<0.05 and p<0.01.

Results

Mean age of the control group (25.91±3.95) was higher than the treatment group (20.57±3.98) (p<0.001) but there was no significant difference between two treatment groups (p=0.184). The mean BMI was statistically similar between control (21.78±3.22) and treatment group (20.98±2.94) (p=0.192).

The mean AMH level of the treatment group at month 6 was significantly lower than the level prior to treatment and that of the control group (p<0.001, p=0.013), although there was no significant difference between the mean AMH level of the treatment group and that of the control group prior to treatment (p=0.967) (Table 1, Figure 1). Mean serum FSH level was found to be increased and T AFC were found to be decreased but these changes were not statistically significant (p=0.912, p=0.824) (Table 1). Mean AMH levels of both low-dose and high-dose groups were found significantly lower at month 6 than the levels before treatment (p=0.005, p<0.001). When the 6th month AMH levels of low and high-dose treatment groups were compared to controls, the mean AMH level was lower in the high-

dose group than controls, while it was not significantly different in the low-dose treatment group than the control group ($p=0.009$, $p=0,097$) (Table 1, Figure 1). Amount of changes in mean AMH, FSH levels and TAFC of low-dose and high-dose groups were not significantly different between baseline and 6th month ($p=0.395$, $p=0.663$, $p=0.584$). Seventeen of 60 patients (28,3%) (10 under low-dose, 7 under high-dose isotretinoin) had MI during treatment (Figure 2). The onset of

the MI were mostly detected at 4th month of the treatment and mean duration was 1.87 ± 1.13 months. While MI became normal during the treatment in most of the cases ($n=11$, 64.7%), it became normal in 4 patients and continued in 2 patients after treatment cessation which were not linked to any gynecological pathology. When AMH, FSH and TAFC were compared between the patients with and without any MI; AMH levels were found to be statistically higher




Figure 1. Mean serum anti-Mullerian hormone levels at baseline and at the end of isotretinoin treatment in the study and control groups
AMH: Anti-Mullerian hormone




Figure 2. Number of the patients who developed menstrual irregularities during isotretinoin treatment

Table 1. Mean levels and mean change in anti-Mullerian hormone, follicle stimulating hormone levels and total antral follicle count at the beginning and at 6th month of isotretinoin treatment in control group and treatment groups and also in patients with and without menstrual irregularities

		Control, (n=32)	Treatment group, (n=60)	Low-dose isotretinoin group, (n=29)	High-dose isotretinoin group, (n=31)	p (*for treatment and control group, **for low dose and high dose group)
		Mean ± SD	Mean ± SD	Mean ± SD	Mean ± SD	
AMH (ng/mL)	Before treatment	6,72±4.79	6.66±4	6.84±4.53	6.48±3.48	0,967*, 0.912**
	Month 6 of the treatment	-	4.82±3.12	5.26±3.67	4.42±2.48	0.013*, 0.569**
	p	-	<0.001	0.005	<0.001	-
	Mean change	-	-1.83±2.57	-1.59±2.85	-2.06±2.3	0.395**
FSH (mIU/mL)	Before treatment	6.53±1.94	6.18±1.82	6.34±2.06	6.02±1.58	0.248*, 0.717**
	Month 6 of the treatment	-	6.47±2.28	6.7±2.91	6.25±1.49	0.765*, 0.853**
	p	-	0.912	0.705	0.631	-
	Mean change	-	0.29±1.7	0.35±1.99	0.23±1.41	0.663**
TAFC	Before treatment	-	9.92±3.36 (10)	10.38±3.45 (10)	9.48±3.27 (9)	0.312**
	Month 6 of the treatment	-	9.72±7.11 (9)	10.83±6.92 (9)	8.68±7.24 (9)	0.256**
	Mean change	-	-0.2±7.86	0.45±7.29	-0.81±8.44	0.584**
		Patients without any menstrual irregularity (n=43)		Patients with menstrual irregularities (n=17)		p
AMH (ng/mL)	Before treatment	5.38±3		9.9±4.44		<0.001
	Month 6 of the treatment	3.99±1.95		6.92±4.40		0.006
	Mean change	-1.38±1.69		-2.98±3.85		0.096
FSH (mIU/mL)	Before treatment	6.42±1.87		5.56±1.58		0.115
	Month 6 of the treatment	6.64±2.41		6.03±1.92		0.517
	Mean change	0.22±1.87		0.46±1.17		0.153
TAFC	Before treatment	9.77±3.58 (10)		10.29±2.8 (9)		0.656
	Month 6 of the treatment	9.30±6.58 (9)		10.76±8.44 (8)		0.687
	Mean change	-0.47±7.38		0.47±9.19		0.730

AMH: Anti-Mullerian hormone, FSH: Follicle stimulating hormone, TAFC: Total antral follicle count, SD: Standard deviation

in the patients with MI than patients without MI at baseline and at 6th month of treatment ($p<0.001$, $p=0.006$), although the mean FSH and TAFC before the treatment and 6th month of the treatment and mean change of all parameters between two groups were not statistically different ($p>0.05$) (Table 1).

Discussion

Several investigations evaluating the isotretinoin's effect on OR had been reported in the past five years and they show significant decreasing levels of AMH with isotretinoin treatment, and they also investigated isotretinoin's effects by evaluating other parameters including TAFC, ovarian volume (OV), FSH, luteinizing hormone (LH), estradiol (E2), testosterone (Table 2). In our study we showed that AMH level decreased significantly following the isotretinoin treatment which was also found to be significantly lower than that of the control group after the treatment. Although mean AMH levels at month 6 was found to be similar between the low dose treatment group and the control group, it was found to be significantly lower in the high-dose treatment group than the control group. Mean change in AMH levels was not significantly different between high-dose and low-dose groups suggesting that the effect of isotretinoin on AMH levels is not dose related. TAFC and FSH level changes were insignificant but it may be due to the early testing of these parameters. There are also studies in the literature evaluating the isotretinoin's effect on pituitary hormones. One of them showed non-significant decreases in mean FSH, E2, progesterone levels while LH and total testosterone decreased significantly¹². The other study showed significant decreases in LH and total testosterone levels while non-significant decrease was observed in the mean FSH level¹³.

OR demonstrates the oocyte quality and the size of the primordial follicle pool accordingly indicates fertility^{14,15}. AMH has been shown as a promising marker of the OR in many studies^{15,16}. It is secreted by granulosa cells in early stages of follicle development (pre-antral and early antral follicles)¹⁵⁻¹⁸. It is the one of the earliest and most predictable marker for ovarian aging, while serum levels of FSH, Inhibin B, and E2 occur relatively late in the reproductive aging^{19,20}. AMH has the best sensitivity and specificity compared to AFC, FSH, E2 and inhibin B levels or various ovarian challenge tests, but basal FSH, LH, inhibin B, or E2 are still in use for long term follow up after CT^{15,18}. AMH shows more rapid and consistent changes in CT treated patients²¹ and it is also useful to evaluate the ovarian damage after surgery, and toxicity caused by ovarian toxic treatments, and radiation^{16,19}.

The mechanism of action and adverse reactions may be associated with isotretinoin's effect on cell apoptosis¹¹. The major mechanism of isotretinoin in patients with acne is sebum suppression. It promotes this action by sebocyte apoptosis²². Isotretinoin shows its mechanism of action on acute promyelocytic leukaemia, and neuroblastoma by inducing apoptosis as well¹¹. Isotretinoin is a prodrug which is isomerized to all-trans-retinoic acid that induces apoptosis in sebaceous glands, meibomian glands, neuroblastoma cells, hypothalamic cells, and other. Therapeutic, adverse, teratogenic and chemopreventive effects of isotretinoin are all mediated by upregulation of Forkhead box O (FoxO) mediated gene transcription²³. Shen et al.²⁴ had reported FoxO1 expression in mouse granulosa cell apoptosis induced by oxidative stress. FoxO-mediated granulosa cell apoptosis may be the explanation of AMH decrease after isotretinoin treatment.

Abali et al.⁹ had first investigated the effects of isotretinoin on OR in

female Sprague-Dawley rats. AMH levels were significantly lower in the treatment group than control group independent from the dose. Lower number of proliferating cell nuclear antigen positive granulosa cells and higher TUNEL-positive granulosa cells were observed in the isotretinoin treated groups. The study showed that percentage of atretic follicles and number of ovarian follicles containing apoptotic granulosa cells was higher in the experimental groups.

Two recent investigations showed that isotretinoin's effect on OR can be reversible^{5,6}. In one of these investigations which was performed on rats it was shown that there were no statistically significant differences in the AMH values one month after treatment cessation compared to pretreatment values, although there was a significant decrease after the treatment⁶. In the other study, all parameters associated with the OR were evaluated and mean AMH, OV and TAFC values at the beginning and 12 months after the treatment cessation were found to be statistically similar although these three parameters decreased significantly just after the treatment⁵. These two studies showed that mean AMH concentrations increased after isotretinoin cessation, and they support that the effect of isotretinoin on ORs might be reversible but the mechanism of increase in AMH levels is controversial. AMH is also used as a predictor of OR in cancer patients and there are also reports showing the OR recovery after CT had been stopped^{25,26}. AMH levels decreased just after the beginning of CT due to destruction of ovarian follicles and increased follicular atresia, but recovery in AMH after CT was reported and it may be associated with reinitiation of follicle growth, the restoration of the small growing follicle pool, which in turn reflects the size on the non-growing, primordial pool^{26,27}. The primordial follicle pool is less damaged when the non-alkylating protocols used so they allow the rapid emergence of newly growing and AMH-secreting follicles although absence of a recovery in high-risk treatment groups may be caused by a profound loss of the primordial follicle pool unable to generate sufficient small growing follicles to secrete AMH^{25,27}. The same mechanism may be an explanation of the isotretinoin's reversible effect on OR.

There are several reports of MI due to isotretinoin treatment²⁸⁻³². Kwon et al.²⁹ reported that 20% (n=8) of the patients had MI during the isotretinoin treatment. Skipped periods in 4 patients, increased interval in two patients, decreased interval and amount in a patient, and intermenstrual bleeding in a patient were reported. Menstruation periods returned to normal after isotretinoin cessation. In another study evaluating the side effects of isotretinoin revealed that 18.6% (n=28) of the patients developed MI (2nd or 3rd month). While menstruation periods returned to normal in most of the cases (n=22) during the treatment³³. Tükenmez Demirci et al.³² reported 28.8% (n=16) of the patients had developed MI; 6 of these patients with prolong interval, 4 with hypomenorhea, 2 with prolonged interval and hypomenorhea, 2 with metrorrhagia, one with shortened interval and one with missed period. In our study group, 28.3% patients (n=17) had MI during treatment which presented mostly as increased interval. MI became normal during the treatment in most of the cases (n=11, 64.7%) which also supports the idea that isotretinoin effects on ovaries are reversible. In our study, AMH levels of patients with MI was higher than that of patients without MI. However no significant difference was observed with regard to mean change of the AMH levels between the patients with MI and patients without MI. High levels of AMH may be an indicator of PCOS but all patients were assessed before and the 6th month of therapy for any gynecologic pathology; none of them had PCOS³⁴. We may suggest that, these patients might have a tendency to

Table 2. Clinical trials which evaluate isotretinoin's effect on hormones, total antral follicle count and ovarian volume

Study	Study year	Cumulative doses and month of the evaluation	Number of patients	Control	AMH (ng/mL)	FSH (mIU/mL)	LH (mIU/mL)	E2 (pg/mL)	Testosterone (free, total) (pg/mL)	TAFc	TOV (mL)
Abali et al. ^{9*}	2013	7.5 or 15 mg/kg/day 1 month	20	10	Significantly lower than the control in both treatment groups	-	-	-	-	-	-
Sikar Aktürk et al. ⁸	2014	120 (mg/kg) 5-7 months	22	22	Significant decrease compare to before the treatment no significant difference compare to control group	-	-	-	-	-	-
Öztürk et al. ¹⁰	2015	120-135 (mg/kg) 5-8 months	32	-	-	Significant decrease	Significant decrease	Significant decrease	-	Non-significant decrease	Non-significant decrease
Aksoy et al. ⁷	2015	120-150 (mg/kg) 6 months	82	-	Significant decrease	Non-significant increase	Non-significant increase	Non-significant decrease	Non-significant decrease	Significant decrease	Significant decrease
Korkmaz et al. ^{6*}	2017	7.5 mg/kg/day 1 month (immediately after the last medication) - on 60 th day - (1 month after the treatment cessation)	8	8	Significant decrease immediately after the treatment No significant difference at 1 month after the treatment cessation and before the treatment	-	-	-	-	-	-
Cinar et al. ⁵	2017	120-150 (mg/kg) 6 month of the treatment 12 months after the treatment cessation	79	-	Significant decrease after the treatment No significant difference at 18 th month and before the treatment	Non-significant increase after the treatment	Non-significant increase after the treatment	Significant decrease after the treatment	Non-significant decrease after the treatment	Significant decrease after the treatment No significant difference at 18 th month and before the treatment	Significant decrease after the treatment No significant difference at 18 th month and before the treatment

*Performed in Sprague-Dawley rats
AMH: Anti-Müllerian hormone, FSH: Follicle stimulating hormone, LH: Luteinizing hormone, TAFc: Total antral follicle count, E2: Estradiol

have PCOS and isotretinoin treatment might have triggered PCOS-like symptoms in those patients who have high AMH levels at baseline. But this observation needs further approval with accordingly designed studies which evaluate AMH levels at the time interval when MI starts.

Study Limitation

Our limitation in this study was that we did not evaluate the AMH levels after a rationale time passed from the treatment cessation.

Conclusion

Isotretinoin is a frequently prescribed drug for patients with acne with well known side effects. Fertility is the major concern of the patients and parents of young adults. Albeit the decrease in AMH level is significant, this effect may be reversible. Studies evaluating AMH levels after a rationale time passed from the treatment cessation are needed. The pathogenesis of MI remains to be determined.

Ethics

Ethics Committee Approval: This study was approved by İstanbul Okmeydanı Training and Research Hospital Institutional Review Board and was conducted according to the Declaration of Helsinki (approval number: 135, date: 05.11.2013).

Informed Consent: Written informed consent was obtained from all participating patients.

Peer-review: Externally peer-reviewed.

Authorship Contributions

Surgical and Medical Practices: E.K., P.K.C., V.M., V.S., Concept: E.K., P.K.C., V.M., V.S., Design: E.K., P.K.C., V.M., V.S., Data Collection or Processing: E.K., P.K.C., V.M., V.S., E.N.D., U.K., Analysis or Interpretation: E.K., P.K.C., V.M., V.S., E.N.D., U.K., Literature Search: E.K., P.K.C., V.M., V.S., E.N.D., Writing: E.K., P.K.C., V.S., E.N.D.

Conflict of Interest: Dr. Emek Kocatürk reports advisory board fees from Novartis, and has served as a medical advisor for Bayer. The other authors have no conflict of interest to declare.

Financial Disclosure: This work was supported by Turkish Society of Dermatology under Grant.

References

- Forbat E, Ali FR, Al-Niामी F: Dermatological indications for the use of isotretinoin beyond acne. *J Dermatolog Treat* 2018;29:698-705.
- Leyden JJ, Del Rosso JQ, Baum EW: The use of isotretinoin in the treatment of acne vulgaris: clinical considerations and future directions. *J Clin Aesthet Dermatol* 2014;7(2 Suppl):S3-S21.
- Khalil S, Bardawil T, Stephan C, et al: Retinoids: A journey from the molecular structures and mechanisms of action to clinical uses in dermatology and adverse effects. *J Dermatolog Treat* 2017;28:684-96.
- Ellis CN, Krach KJ: Uses and complications of isotretinoin therapy. *J Am Acad Dermatol* 2001;45:150-7.
- Cinar SL, Kartal D, Aksoy H, et al: Long-term effect of systemic isotretinoin on female fertility. *Cutan Ocul Toxicol* 2017;36:132-4.
- Korkmaz E, Cetinkaya N, Oz M, et al: The possibly reversible isotretinoin effect of decreased ovarian reserve in sprague-dawley albinos: Part I, biochemical analyses. *Gynecol Obstet Invest* 2017;82:72-7.
- Aksoy H, Cinar L, Acmaz G, et al: The effect of isotretinoin on ovarian reserve based on hormonal parameters, ovarian volume, and antral follicle count in women with acne. *Gynecol Obstet Invest* 2015;79:78-82.
- Sikar Aktürk A, Abalı R, Yüksel MA, Çelik Güzel E, Güzel S, Kıran R: The effects of isotretinoin on the ovarian reserve of females with acne. *Gynecol Endocrinol* 2014;30:30-3.
- Abalı R, Yüksel MA, Aktas C, et al: Decreased ovarian reserve in female Sprague-Dawley rats induced by isotretinoin (retinoic acid) exposure. *Reprod Biomed Online* 2013;27:184-91.
- Öztürk S, Öztürk T, Ucak H, et al: Evaluation of ovarian reserve and function in female patients treated with oral isotretinoin for severe acne: an exploratory study. *Cutan Ocul Toxicol* 2015;34:21-4.
- Melnik BC: Apoptosis May Explain the Pharmacological Mode of Action and Adverse Effects of Isotretinoin, Including Teratogenicity. *Acta Derm Venereol* 2017;97:173-81.
- Karadag AS, Ertugrul DT, Tatal E, Akin KO: Isotretinoin influences pituitary hormone levels in acne patients. *Acta Derm Venereol* 2011;91:31-4.
- Karadag AS, Takci Z, Ertugrul DT, Bilgili SG, Balahoroglu R, Takir M: The effect of different doses of isotretinoin on pituitary hormones. *Dermatology* 2015;230:354-9.
- Grujters MJG, Visser JA, Durlinger AL, Themmen AP: Anti-müllerian hormone and its role in ovarian function. *Mol Cell Endocrinol* 2003;211:85-90.
- Kunt C, Ozaksit G, Keskin Kurt R, et al: Anti-Mullerian hormone is a better marker than inhibin B, follicle stimulating hormone, estradiol or antral follicle count in predicting the outcome of in vitro fertilization. *Arch Gynecol Obstet* 2011;283:1415-21.
- Iwase A, Nakamura T, Nakahara T, Goto M, Kikkawa F: Anti-Müllerian hormone and assessment of ovarian reserve after ovarian toxic treatment: a systematic narrative review. *Reprod Sci* 2015;22:519-26.
- Kruszyńska A, Słowińska-Szrednicka J: Anti-Müllerian hormone (AMH) as a good predictor of time of menopause. *Prz Menopauzalny* 2017;16:47-50.
- Broer SL, Broekmans FJ, Laven JS, Fauser BC: Anti-Müllerian hormone: ovarian reserve testing and its potential clinical implications. *Hum Reprod Update* 2014;20:688-701.
- Iwase A, Osuka S, Nakamura T, et al: Usefulness of the Ultrasensitive Anti-Müllerian Hormone Assay for Predicting True Ovarian Reserve. *Reprod Sci* 2016;23:756-60.
- Singh N, Malik E, Banerjee A, Chosdol K, Sreenivas V, Mittal S: "Anti-Müllerian Hormone: Marker for Ovarian Response in Controlled Ovarian Stimulation for IVF Patients": A First Pilot Study in the Indian Population. *J Obstet Gynaecol India* 2013;63:268-72.
- Fréour T, Barrière P, Masson D: Anti-müllerian hormone levels and evolution in women of reproductive age with breast cancer treated with chemotherapy. *Eur J Cancer* 2017;74:1-8.
- Nelson AM, Gilliland KL, Cong Z, Thiboutot DM: 13-cis Retinoic acid induces apoptosis and cell cycle arrest in human SEB-1 sebocytes. *J Invest Dermatol* 2006;126:2178-89.
- Melnik BC: Isotretinoin and FoxO1: A scientific hypothesis. *Dermatoendocrinol* 2011;3:141-65.
- Shen M, Lin F, Zhang J, Tang Y, Chen WK, Liu H: Involvement of the up-regulated FoxO1 expression in follicular granulosa cell apoptosis induced by oxidative stress. *J Biol Chem* 2012;287:25727-40.
- Peigné M, Decanter C: Serum AMH level as a marker of acute and long-term effects of chemotherapy on the ovarian follicular content: a systematic review. *Reprod Biol Endocrinol* 2014;12:26.
- Dillon KE, Sammel MD, Prewitt M, et al: Pretreatment antimüllerian hormone levels determine rate of posttherapy ovarian reserve recovery: acute changes in ovarian reserve during and after chemotherapy. *Fertil Steril* 2013;99:477-83.
- Brougham MF, Crofton PM, Johnson EJ, Evans N, Anderson RA, Wallace WH: Anti-Müllerian hormone is a marker of gonadotoxicity in pre- and postpubertal girls treated for cancer: a prospective study. *J Clin Endocrinol Metab* 2012;97:2059-67.
- Christmas T: Roaccutane and menorrhagia. *J Am Acad Dermatol*. 1988;18:576-7.
- Kwon HJ, Lee JY, Cho BK, Park HJ: Menstrual irregularity during isotretinoin treatment. *J Eur Acad Dermatol Venereol* 2007;21:562-3.
- Cox NH: Amenorrhoea during treatment with isotretinoin. *Br J Dermatol* 1988;118:857-8.
- McElwee NE, Schumacher MC, Johnson SC et al: An observational study of isotretinoin recipients treated for acne in a health maintenance organization. *Arch Dermatol* 1991;127:341-6.
- Tükenmez Demirci G, Mertoğlu E, Kivanç Altunay İ, Atış G, Küçükünal A: The investigation of the frequency of menstrual irregularity and hypertrichosis due to isotretinoin usage in female patients. *Turkderm* 2014;48:152-5.
- Karadağ AS, Calka O, Akdeniz N: Evaluation of Side Effects of Isotretinoin in 150 Patients with Acne Vulgaris. *Turkderm* 2011;45:37-42.
- Casadei L, Fanisio F, Sorge RP, Collamarini M, Piccolo E, Piccione E: The diagnosis of PCOS in young infertile women according to different diagnostic criteria: the role of serum anti-Müllerian hormone. *Arch Gynecol Obstet* 2018;298:207-15.